Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.
暂无分享,去创建一个
Piotr Sliz | Mohammad Azam | Tomi K Sawyer | G. Daley | R. Bohacek | W. Bornmann | D. Veach | B. Clarkson | T. Sawyer | M. Azam | W. Shakespeare | V. Nardi | George Q Daley | Darren R Veach | Yihan Wang | Bayard Clarkson | R. Sundaramoorthi | Chester A Metcalf | Raji Sundaramoorthi | David C Dalgarno | William C Shakespeare | D. Dalgarno | Valentina Nardi | Regine S Bohacek | William G Bornmann | Yihan Wang | C. Metcalf | P. Śliż
[1] G. Superti-Furga,et al. Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase , 2003, Cell.
[2] P. N. Rao,et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.
[3] T. Boggon,et al. Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. , 2005, Blood.
[4] H. Varmus,et al. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.
[5] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[6] J. Kuriyan,et al. Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. , 2002, Cancer research.
[7] John Kuriyan,et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). , 2001, Cancer research.
[8] P. Seeburg,et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.
[9] J. Kuriyan,et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.
[10] D. Fabbro,et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease. , 2003, Cancer cell.
[11] B. Druker,et al. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. , 2003, Blood.
[12] M. Meyerson,et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.
[13] M. Speicher,et al. A Cell-Based Screening Strategy That Predicts Mutations in Oncogenic Tyrosine Kinases: Implications for Clinical Resistance in Targeted Cancer Treatment , 2005, Cell cycle.
[14] Ping Chen,et al. Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.
[15] G. Daley,et al. Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL , 2003, Cell.
[16] Donna Neuberg,et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. , 2005, Cancer cell.
[17] W. Bornmann,et al. Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors. , 2003, Cancer research.
[18] C. Sawyers,et al. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[19] Ola Engkvist,et al. Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. , 2004, Chemistry & biology.
[20] G. Daley,et al. A screen to identify drug resistant variants to target-directed anti-cancer agents , 2003, Biological Procedures Online.
[21] R. Larson,et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. , 2002, Blood.
[22] L. Wodicka,et al. A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.
[23] P. Nguyen,et al. Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate. , 2004, Archives of pathology & laboratory medicine.
[24] G. Superti-Furga,et al. A Myristoyl/Phosphotyrosine Switch Regulates c-Abl , 2003, Cell.
[25] William Pao,et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[26] R. A. Etten,et al. Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain , 2001, Oncogene.
[27] Susan Adams,et al. Structural Basis of Src Tyrosine Kinase Inhibition with a New Class of Potent and Selective Trisubstituted Purine‐based Compounds , 2006, Chemical biology & drug design.
[28] P. Paschka,et al. Molecular Surveillance of Chronic Myeloid Leukemia Patients in the Imatinib Era – Evaluation of Response and Resistance , 2004, Acta Haematologica.
[29] S. Faderl,et al. Monitoring of minimal residual disease in chronic myeloid leukemia. , 2004, Hematology/oncology clinics of North America.
[30] S. Harrison,et al. Variation on an Src-like Theme , 2003, Cell.
[31] R. Jove,et al. The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. , 2000, Cancer research.
[32] John Kuriyan,et al. Crystal structure of the Src family tyrosine kinase Hck , 1997, Nature.
[33] J. Kuriyan,et al. Activation of the Sire-family tyrosine kinase Hck by SH3 domain displacement , 1997, Nature.
[34] C. Sawyers,et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.
[35] B. Druker,et al. Oncogenes and Tumor Suppressors (795 articles) , 2004 .
[36] Michael J. Eck,et al. Three-dimensional structure of the tyrosine kinase c-Src , 1997, Nature.
[37] G. Superti-Furga,et al. Crosstalk between the catalytic and regulatory domains allows bidirectional regulation of Src , 2000, Nature Structural Biology.
[38] T. Clackson,et al. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. , 2004, Blood.
[39] G. Superti-Furga,et al. Autoinhibition of c-Abl , 2002, Cell.